Abstract
Coffee is one of the most widely consumed beverages. We performed a genome-wide association study (GWAS) of coffee intake in US-based 23andMe participants (N=130,153) and identified 7 significant loci, with many replicating in three multi-ancestral cohorts. We examined genetic correlations and performed a phenome-wide association study across thousands of biomarkers and health and lifestyle traits, then compared our results to the largest available GWAS of coffee intake from UK Biobank (UKB; N=334,659). The results of these two GWAS were highly discrepant. We observed positive genetic correlations between coffee intake and psychiatric illnesses, pain, and gastrointestinal traits in 23andMe that were absent or negative in UKB. Genetic correlations with cognition were negative in 23andMe but positive in UKB. The only consistent observations were positive genetic correlations with substance use and obesity. Our study shows that GWAS in different cohorts could capture cultural differences in the relationship between behavior and genetics.
Competing Interest Statement
PF and SLE are employees of 23andMe, Inc., and hold stock or stock options in 23andMe. AAP is on the scientific advisory board of Vivid Genomics for which he receives stock options.
Funding Statement
This study was funded by the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), the National Institute of Health (P50DA037844, R01 MH113362), the National Institute on Drug Abuse (DP1DA054394), a Natural Science and Engineering Research Council PGS-D Scholarship, a Canadian Institutes of Health Research Postdoctoral Fellowship, a Canadian Institutes of Health Research Canada Research Chair in Translational Neuropsychopharmacology, the National Institute of Mental Health (R25MH081482), the Institute for Health and Care Research Maudsley Biomedical Research Centre, the Maudsley National Health Services Foundation Trust, and Kings College London.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical & Independent Review Services of Salus IRB gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
We will provide 23andMe summary statistics for the top 10,000 SNPs upon publication. Full GWAS summary statistics will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit (https://research.23andme.com/collaborate/#dataset-access/) for more information and to apply to access the data.
